Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MEPIVACAINE HYDROCHLORIDE W/ LEVONORDEFRIN vs ISOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Local anesthetic that blocks voltage-gated sodium channels in neuronal membranes, preventing propagation of action potentials and transmission of pain signals.
Isocaine hydrochloride (mepivacaine) is an amino amide local anesthetic that blocks sodium ion channels in nerve cell membranes, thereby inhibiting the initiation and conduction of nerve impulses. Levonordefrin is a vasoconstrictor that acts on alpha-adrenergic receptors to cause local vasoconstriction, prolonging the anesthetic effect.
Local and regional infiltration anesthesia,Peripheral nerve blocks,Dental anesthesia
Local anesthesia for dental procedures,Local anesthesia for surgical procedures,Infiltration anesthesia,Nerve block anesthesia
Dental infiltration or nerve block: 1-2 cartridges (36-72 mg mepivacaine; 0.009-0.018 mg levonordefrin) of 2% solution with 1:20,000 levonordefrin; maximum dose: 4.4 mg/kg mepivacaine (not to exceed 300 mg) per appointment.
Adult dental infiltration or nerve block: 1-2 m L of 2% solution (20 mg/m L isocaine hydrochloride with levonordefrin 1:20,000) administered subcutaneously; maximum single dose 5 m L (100 mg isocaine hydrochloride); maximum total dose 7 m L per appointment.
Terminal elimination half-life is approximately 2-3 hours in adults. In neonates, half-life is prolonged (8-10 hours due to immature hepatic function). Clinical context: Short half-life reduces risk of systemic accumulation with repeated doses.
Terminal elimination half-life is approximately 2.1 hours; clinically, accumulation may occur with repeated doses in renal impairment.
Primarily hepatic via N-demethylation by CYP1A2; minor metabolism by CYP3A4. Metabolites excreted renally.
Isocaine hydrochloride (mepivacaine) is primarily metabolized in the liver by cytochrome P450 enzymes, mainly CYP1A2 and CYP3A4, to inactive metabolites. Levonordefrin is metabolized by monoamine oxidase (MAO) and catechol-O-methyltransferase (COMT).
Mepivacaine is primarily metabolized in the liver via N-demethylation and hydroxylation. Less than 5% is excreted unchanged in urine. Hepatic clearance accounts for >90% of elimination; renal excretion of metabolites accounts for the remainder. Fecal elimination is minimal (<2%).
Renal excretion of metabolites, primarily 4-hydroxy-2,6-dimethylaniline glucuronide and sulfate conjugates; less than 5% excreted unchanged in urine.
Approximately 75-85% bound to alpha-1-acid glycoprotein (orosomucoid) and less extensively to albumin. Binding is concentration-dependent.
Approximately 60% bound to plasma proteins, primarily alpha-1-acid glycoprotein.
Volume of distribution (Vd) is approximately 0.8-1.0 L/kg, indicating extensive tissue distribution. Higher Vd in infants (2-3 L/kg) due to larger extracellular fluid compartment.
Vd is approximately 1.0 L/kg; distribution is rapid and extensive, indicating high tissue uptake.
Mepivacaine is not administered orally due to extensive first-pass metabolism. For local infiltration or regional administration, bioavailability is essentially 100% at the site of administration. Intravenous bioavailability is 100% by definition.
Intravenous: 100%; Intramuscular: ~100%; Subcutaneous: ~100%; Oral: 10-30% due to first-pass metabolism.
GFR ≥ 50 m L/min: no adjustment. GFR 30-49 m L/min: consider reducing dose by 25% due to potential accumulation of metabolites. GFR < 30 m L/min: avoid or use with caution; reduce dose by 50% and monitor for CNS toxicity.
No specific dosing adjustment required for mild to moderate renal impairment; for severe impairment (GFR <30 m L/min), consider reducing dose by 25-50% due to risk of methemoglobinemia; monitor methemoglobin levels.
Child-Pugh A: no adjustment. Child-Pugh B: consider 50% dose reduction. Child-Pugh C: contraindicated due to impaired metabolism and risk of toxicity.
Child-Pugh Class A: No adjustment. Class B: Reduce dose by 50%; maximum single dose 50 mg. Class C: Avoid use or use with extreme caution; alternative agent recommended.
Children: 1.1-1.8 mg/kg mepivacaine (0.54-0.9 mg/lb) as 2% solution with 1:20,000 levonordefrin; maximum 4.4 mg/kg (not exceeding 300 mg). For example, 20 kg child: 22-36 mg mepivacaine (1.1-1.8 m L of 2% solution).
Weight-based dose: 1-2 mg/kg isocaine hydrochloride per injection, maximum 4.4 mg/kg total; not to exceed adult doses. For dental procedures, typical dose 0.5-1 m L per injection site depending on weight.
Elderly patients (≥65 years): use lowest effective dose due to increased sensitivity, potential renal impairment, and comorbidities. Maximum single dose: 4.4 mg/kg (not exceeding 300 mg); reduce dose by 50% if GFR < 50 m L/min. Monitor cardiovascular status due to levonordefrin.
Elderly patients (≥65 years): Reduced dose due to decreased hepatic metabolism; initial dose 50% of adult dose; maximum single dose 50 mg; monitor for CNS and cardiovascular side effects.
Not available.
Intravascular injection of local anesthetics can cause sudden cardiac arrest, especially in children. Resuscitative equipment and personnel trained in advanced cardiac life support must be immediately available.
Risk of central nervous system toxicity (seizures, CNS depression),Cardiovascular toxicity (arrhythmias, hypotension) with high doses or rapid absorption,Avoid in patients with severe liver disease,May cause methemoglobinemia, especially in patients with glucose-6-phosphate dehydrogenase deficiency
Risk of systemic toxicity from inadvertent intravascular injection,Caution in patients with hepatic impairment due to reduced metabolism,Caution in patients with cardiovascular disease due to vasoconstrictor effects of levonordefrin,Avoid use in patients with severe hypertension or thyrotoxicosis,Use lowest effective dose to minimize risk of adverse effects
Hypersensitivity to mepivacaine or other amide-type local anesthetics,Severe hypotension or cardiogenic shock,Porphyria,Administration via intravenous regional anesthesia (Bier block)
Hypersensitivity to mepivacaine, levonordefrin, or other amide-type local anesthetics,Severe hypotension or cardiogenic shock,Thromboembolic disease,Use of MAO inhibitors or tricyclic antidepressants within 14 days,Severe hypertension or thyrotoxicosis
Avoid high-tyramine foods (aged cheese, cured meats, fermented products) as concurrent MAO-A inhibition from levonordefrin may cause hypertensive crisis. Limit caffeine intake (stimulant additive effect on heart rate).
No significant food interactions. Avoid alcohol before and after dental procedure to reduce risk of bleeding and enhanced sedation.
Mepivacaine hydrochloride with levonordefrin is classified as FDA Pregnancy Category C. In animal studies, mepivacaine has been associated with adverse fetal effects at high doses, but no well-controlled human studies exist. Levonordefrin is a vasoconstrictor; systemic absorption may reduce uterine blood flow, potentially causing fetal hypoxia. Risk in the first trimester is unknown; second and third trimester use may be associated with fetal bradycardia and acidosis if high doses are administered or inadvertent intravascular injection occurs. Use only if clearly needed.
In the first trimester, no well-controlled studies in humans; animal studies insufficient. In second and third trimesters, lidocaine (component) crosses placenta with fetal serum levels ~50% maternal; no major teratogenic risk in typical doses. Levonordefrin is a vasoconstrictor; risk of uteroplacental insufficiency at high doses. Avoid during first trimester if possible.
Mepivacaine is excreted into breast milk in small amounts; the milk-to-plasma ratio is approximately 0.4-0.6. Levonordefrin is not expected to enter breast milk significantly. The American Academy of Pediatrics considers mepivacaine compatible with breastfeeding. However, observe the infant for signs of local anesthetic toxicity (e.g., drowsiness, irritability).
Lidocaine excreted into breast milk in small amounts (<1% maternal dose); M/P ratio ~0.3-0.6. Levonordefrin likely minimal excretion. Compatible with breastfeeding with caution; avoid large doses.
No specific dose adjustment is recommended for mepivacaine in pregnancy; however, plasma levels of mepivacaine may be lower due to increased volume of distribution and clearance. Use the lowest effective dose and avoid high doses or frequent administration to minimize fetal exposure. Levonordefrin dose should be limited to minimize vasoconstriction effects.
No routine dose adjustments required for lidocaine in pregnancy. However, increased plasma volume and cardiac output may reduce peak concentrations; consider using lowest effective dose and avoiding excessive levonordefrin to prevent uterine vasoconstriction. Use with caution in preeclampsia or hypertension.
For dental procedures, limit dose to 1 cartridge (1.8 m L) per appointment due to levonordefrin's α-adrenergic effects. Avoid in patients with sulfite allergy (bisulfite preservative). Use with caution in severe cardiovascular disease, pheochromocytoma, or hyperthyroidism due to levonordefrin. Onset 2-3 min, duration 60-90 min (infiltration).
ISOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN is a dental anesthetic combination. Levonordefrin is a vasoconstrictor that prolongs anesthetic action. Avoid intravascular injection to prevent systemic toxicity. Use caution in patients with cardiovascular disease, hypertension, or hyperthyroidism due to levonordefrin. Maximum dose: 5.4 mg/kg of isocaine base. Contraindicated in patients with sulfite allergy (contains sodium metabisulfite).
Report any history of heart disease, high blood pressure, or sulfite allergy before injection.,You may feel temporary increased heart rate or palpitations due to the vasoconstrictor.,Numbness may last several hours; avoid chewing gum or eating until sensation returns.,Seek immediate medical attention if you experience chest pain, severe headache, or difficulty breathing.,Use only as directed by your dentist; do not exceed prescribed dose.
You will receive an injection for dental numbness lasting about 1-3 hours.,Avoid chewing on the numbed area to prevent accidental injury.,Do not eat or drink hot liquids until sensation fully returns.,Report any signs of allergic reaction (rash, swelling, difficulty breathing) immediately.,Inform your dentist if you have heart disease, high blood pressure, or thyroid problems.
"Concomitant use of prochlorperazine and mepivacaine may lead to additive central nervous system (CNS) depression, resulting in excessive sedation, respiratory depression, and increased risk of hypotension. Mepivacaine, a local anesthetic, can cause CNS excitation followed by depression, while prochlorperazine, a phenothiazine antipsychotic, directly depresses CNS function. This combination may also potentiate cardiotoxicity, including QT prolongation and arrhythmias, due to additive effects on cardiac conduction."
"Mepivacaine, an amide local anesthetic, and Dezocine, a mixed opioid agonist-antagonist, both exhibit dose-dependent central nervous system (CNS) depressant and respiratory depressant effects. When co-administered, additive or supra-additive CNS and respiratory depression can occur, leading to increased risk of sedation, confusion, respiratory depression, and potentially coma or apnea, particularly in patients with compromised respiratory function or those receiving high doses of either agent."
"The combination of gamma-hydroxybutyric acid (GHB) and mepivacaine can lead to additive central nervous system (CNS) depression and respiratory depression. Both drugs act as CNS depressants, with GHB enhancing GABAergic activity and mepivacaine blocking sodium channels, which may result in severe sedation, respiratory arrest, and hypotension. Concomitant use requires careful risk-benefit assessment and close monitoring."
"Levonordefrin, a vasoconstrictor with beta-agonist activity, may counteract the beta-blocking effects of pindolol, leading to unopposed alpha-adrenergic stimulation and potential hypertensive crisis. Additionally, pindolol's intrinsic sympathomimetic activity (ISA) may interact with levonordefrin, increasing the risk of cardiac arrhythmias and AV block due to conflicting adrenergic signaling. Clinically, this can result in severe hypertension, bradycardia, or heart block, especially in patients with underlying cardiovascular disease."
"Mianserin, a tetracyclic antidepressant with potent alpha-2-adrenergic receptor antagonism, can reduce the vasopressor response to Levonordefrin, a direct-acting alpha-1 adrenergic agonist. This interaction occurs because Mianserin blocks presynaptic alpha-2 receptors, leading to increased norepinephrine release and potential receptor desensitization, as well as possible competitive antagonism at the alpha-1 receptor. Clinically, this may result in diminished efficacy of Levonordefrin when used as a local vasoconstrictor during dental or surgical procedures, potentially leading to inadequate hemostasis or reduced local anesthesia duration."
"Levonordefrin, a sympathomimetic amine with alpha- and beta-adrenergic agonist activity, can enhance the negative dromotropic effect of arotinolol, a non-selective beta-blocker with intrinsic sympathomimetic activity. This results in additive depression of atrioventricular (AV) nodal conduction, potentially leading to prolonged PR interval, second- or third-degree AV block, and symptomatic bradycardia. Clinically, patients may present with dizziness, syncope, or hemodynamic instability, particularly in those with pre-existing conduction abnormalities."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MEPIVACAINE HYDROCHLORIDE W/ LEVONORDEFRIN vs ISOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN, answered by our medical review team.
MEPIVACAINE HYDROCHLORIDE W/ LEVONORDEFRIN is a Local Anesthetic with Vasoconstrictor that works by Local anesthetic that blocks voltage-gated sodium channels in neuronal membranes, preventing propagation of action potentials and transmission of pain signals.. ISOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN is a Local Anesthetic with Vasoconstrictor that works by Isocaine hydrochloride (mepivacaine) is an amino amide local anesthetic that blocks sodium ion channels in nerve cell membranes, thereby inhibiting the initiation and conduction of nerve impulses. Levonordefrin is a vasoconstrictor that acts on alpha-adrenergic receptors to cause local vasoconstriction, prolonging the anesthetic effect.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MEPIVACAINE HYDROCHLORIDE W/ LEVONORDEFRIN and ISOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN depend on the specific clinical indication. These are both Local Anesthetic with Vasoconstrictor agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MEPIVACAINE HYDROCHLORIDE W/ LEVONORDEFRIN is: Dental infiltration or nerve block: 1-2 cartridges (36-72 mg mepivacaine; 0.009-0.018 mg levonordefrin) of 2% solution with 1:20,000 levonordefrin; maximum dose: 4.4 mg/kg mepivacaine (not to exceed 300 mg) per appointment.. The standard adult dose of ISOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN is: Adult dental infiltration or nerve block: 1-2 m L of 2% solution (20 mg/m L isocaine hydrochloride with levonordefrin 1:20,000) administered subcutaneously; maximum single dose 5 m L (100 mg isocaine hydrochloride); maximum total dose 7 m L per appointment.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MEPIVACAINE HYDROCHLORIDE W/ LEVONORDEFRIN and ISOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MEPIVACAINE HYDROCHLORIDE W/ LEVONORDEFRIN is classified as Category C. Mepivacaine hydrochloride with levonordefrin is classified as FDA Pregnancy Category C. In animal studies, mepivacaine has been associated with adverse fetal effects at high doses,. ISOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN is classified as Category C. In the first trimester, no well-controlled studies in humans; animal studies insufficient. In second and third trimesters, lidocaine (component) crosses placenta with fetal serum l. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.